Alline Cristina Campos1, Francisco Silveira Guimarães. 1. Department of Pharmacology, School of Medicine of Ribeirão Preto, Campus USP, Av. Bandeirantes 3900, Monte Alegre, Ribeirão Preto, SP, Brazil.
Abstract
RATIONALE: Cannabidiol (CBD) is a non-psychotomimetic constituent of Cannabis sativa plant that induces anxiolytic effects. However, the brain sites and mechanisms of these effects remain poorly understood. The dorsolateral periaqueductal gray (dlPAG) is a midbrain structure related to anxiety that contains receptors proposed to interact with CBD such as 5HT1A. In addition, since CBD has been shown to inhibit anandamide metabolism, CB1 receptors could also be involved in the effects of this cannabinoid. OBJECTIVES: To investigate if the dlPAG could be a possible site of the anxiolytic effects induced by CBD and if these effects depend on CB1 or 5HT1A receptors. MATERIALS AND METHODS: Male Wistar rats with cannulae aimed at the dlPAG were tested in the elevated plus maze (EPM) and the Vogel conflict test (VCT). RESULTS: CBD injected into the dlPAG produced anxiolytic-like effects in the EPM with a bell-shaped dose-response curve. The anxiolytic effect of CBD was confirmed in the VCT. These effects were prevented by WAY100635, a 5HT1A receptor antagonist, but not by AM251, an antagonist of CB1 receptors. CONCLUSION: These results suggest the CBD interacts with 5HT1A receptors to produce anxiolytic effects in the dlPAG.
RATIONALE: Cannabidiol (CBD) is a non-psychotomimetic constituent of Cannabis sativa plant that induces anxiolytic effects. However, the brain sites and mechanisms of these effects remain poorly understood. The dorsolateral periaqueductal gray (dlPAG) is a midbrain structure related to anxiety that contains receptors proposed to interact with CBD such as 5HT1A. In addition, since CBD has been shown to inhibit anandamide metabolism, CB1 receptors could also be involved in the effects of this cannabinoid. OBJECTIVES: To investigate if the dlPAG could be a possible site of the anxiolytic effects induced by CBD and if these effects depend on CB1 or 5HT1A receptors. MATERIALS AND METHODS: Male Wistar rats with cannulae aimed at the dlPAG were tested in the elevated plus maze (EPM) and the Vogel conflict test (VCT). RESULTS:CBD injected into the dlPAG produced anxiolytic-like effects in the EPM with a bell-shaped dose-response curve. The anxiolytic effect of CBD was confirmed in the VCT. These effects were prevented by WAY100635, a 5HT1A receptor antagonist, but not by AM251, an antagonist of CB1 receptors. CONCLUSION: These results suggest the CBD interacts with 5HT1A receptors to produce anxiolytic effects in the dlPAG.
Authors: M Hamon; L Lanfumey; S el Mestikawy; C Boni; M C Miquel; F Bolaños; L Schechter; H Gozlan Journal: Neuropsychopharmacology Date: 1990 Oct-Dec Impact factor: 7.853
Authors: Fabrício A Moreira; Daniele C Aguiar; Francisco S Guimarães Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 2006-07-31 Impact factor: 5.067
Authors: T Rubino; N Realini; C Castiglioni; C Guidali; D Viganó; E Marras; S Petrosino; G Perletti; M Maccarrone; V Di Marzo; D Parolaro Journal: Cereb Cortex Date: 2007-10-05 Impact factor: 5.357
Authors: Tom P Freeman; Chandni Hindocha; Gianluca Baio; Natacha D C Shaban; Emily M Thomas; Danica Astbury; Abigail M Freeman; Rachel Lees; Sam Craft; Paul D Morrison; Michael A P Bloomfield; Dominic O'Ryan; Jane Kinghorn; Celia J A Morgan; Ali Mofeez; H Valerie Curran Journal: Lancet Psychiatry Date: 2020-07-28 Impact factor: 27.083
Authors: Sachin Patel; Mathew N Hill; Joseph F Cheer; Carsten T Wotjak; Andrew Holmes Journal: Neurosci Biobehav Rev Date: 2017-05 Impact factor: 8.989